PMID- 15213147
OWN - NLM
STAT- MEDLINE
DCOM- 20040806
LR  - 20220129
IS  - 0019-9567 (Print)
IS  - 1098-5522 (Electronic)
IS  - 0019-9567 (Linking)
VI  - 72
IP  - 7
DP  - 2004 Jul
TI  - Chemotherapy for schistosomiasis in Ugandan fishermen: treatment can cause a 
      rapid increase in interleukin-5 levels in plasma but decreased levels of 
      eosinophilia and worm-specific immunoglobulin E.
PG  - 4023-30
AB  - Chemotherapy for blood-dwelling schistosomes kills the worms and exposes parasite 
      antigen to the circulation. In many people from areas of endemicity, this 
      treatment increases parasite-specific immunoglobulin E (IgE) and other Th2 
      responses in the months following therapy, responses that have been associated 
      with subsequent resistance to reinfection. Here we investigate much earlier 
      changes in immune reactions after praziquantel therapy in Schistosoma 
      mansoni-infected fishermen working in an area of high transmission in Uganda. The 
      subjects gave blood before treatment and at 1 and 21 days posttreatment. Blood 
      cultures were incubated with schistosome soluble worm antigen (SWA) or soluble 
      egg antigen (SEA). Interleukin-4 (IL-4), IL-5, IL-10, IL-13, gamma interferon, 
      and transforming growth factor beta levels were measured in the cultures and in 
      plasma. A marked transient increase in plasma IL-5 levels was observed in 75% of 
      the subjects (n = 48) by 1 day posttreatment. This response was dependent on 
      pretreatment intensity of infection and was accompanied by a transient decrease 
      in eosinophil numbers. One day posttreatment, blood cultures from the 16 subjects 
      with the greatest increase in plasma IL-5 level (>100 pg/ml) displayed reduced 
      IL-5, IL-13, and IL-10 responses to SWA, and in contrast to the rest of the 
      cohort, these high-IL-5 subjects displayed reduced levels of SWA-specific IgE in 
      plasma 21 days posttreatment. Twenty months after treatment, the intensity of 
      reinfection was positively correlated with the increase in plasma IL-5 level seen 
      1 day posttreatment. These studies describe the heterogeneity in early immune 
      reactions to treatment, identifying subgroups who have different patterns of 
      reaction and who may have different capacities to mount the responses that have 
      been associated with resistance to reinfection.
FAU - Fitzsimmons, Colin M
AU  - Fitzsimmons CM
AD  - Department of Pathology, University of Cambridge, Cambridge, United Kingdom. 
      cmf1000@cam.ac.uk
FAU - Joseph, Sarah
AU  - Joseph S
FAU - Jones, Frances M
AU  - Jones FM
FAU - Reimert, Claus M
AU  - Reimert CM
FAU - Hoffmann, Karl F
AU  - Hoffmann KF
FAU - Kazibwe, Francis
AU  - Kazibwe F
FAU - Kimani, Gachuhi
AU  - Kimani G
FAU - Mwatha, Joseph K
AU  - Mwatha JK
FAU - Ouma, John H
AU  - Ouma JH
FAU - Tukahebwa, Edridah M
AU  - Tukahebwa EM
FAU - Kariuki, Henry C
AU  - Kariuki HC
FAU - Vennervald, Birgitte J
AU  - Vennervald BJ
FAU - Kabatereine, Narcis B
AU  - Kabatereine NB
FAU - Dunne, David W
AU  - Dunne DW
LA  - eng
GR  - G7708609/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Infect Immun
JT  - Infection and immunity
JID - 0246127
RN  - 0 (Anthelmintics)
RN  - 0 (Interleukin-5)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 6490C9U457 (Praziquantel)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Animals
MH  - Anthelmintics/pharmacology
MH  - Eosinophils/*metabolism
MH  - Humans
MH  - Immunoglobulin E/*blood/immunology
MH  - Interleukin-5/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Praziquantel/pharmacology
MH  - Schistosoma/*drug effects/immunology
MH  - Schistosomiasis/*drug therapy/immunology
MH  - Uganda
PMC - PMC427444
EDAT- 2004/06/24 05:00
MHDA- 2004/08/07 05:00
PMCR- 2004/07/01
CRDT- 2004/06/24 05:00
PHST- 2004/06/24 05:00 [pubmed]
PHST- 2004/08/07 05:00 [medline]
PHST- 2004/06/24 05:00 [entrez]
PHST- 2004/07/01 00:00 [pmc-release]
AID - 72/7/4023 [pii]
AID - 1600-03 [pii]
AID - 10.1128/IAI.72.7.4023-4030.2004 [doi]
PST - ppublish
SO  - Infect Immun. 2004 Jul;72(7):4023-30. doi: 10.1128/IAI.72.7.4023-4030.2004.